| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 9 | 290.9x | 17.3x | Bottom tier | |
Growth | 86 | 13.9% | 7.1% | Top tier | |
Quality | 73 | 2.0% | 4.5% | Top tier | |
Safety | 82 | — | 2.6x | Top tier | |
Capital Return | 44 | 0.00% | 0.06% | Around median | |
Momentum | 99 | 62.2% | -1.6% | Top tier | |
Sentiment | 43 | 6 | 3 | Around median |
The floor: what the company is worth if growth stopped today
93% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
AtriCure is a medical device company focused on surgical treatments for atrial fibrillation, left atrial appendage management, and pain management through cryogenic nerve blocking. Its revenue is distributed across open surgical ablation, appendage management with AtriClip products, pain management with the cryoSPHERE MAX and cryoXT probes, and minimally invasive ablation, while adoption is supported by global field and education teams comprising more than 500 people.
In quarter 2 of fiscal year 2026, revenue reached $153.6 million, up 12.8% year over year and 8.7% from the previous quarter, including $125.6 million in the United States and $28 million internationally. Within the United States, open ablation generated $40.9 million, appendage management $51.6 million, and pain management $27.1 million, while minimally invasive ablation contributed approximately $6 million; revenue in Europe reached $17.2 million, and revenue in Asia-Pacific and other international markets reached $10.8 million.
Gross profit reached $118.6 million in quarter 2 of fiscal year 2026, equivalent to a gross margin of 77.2%, up approximately 270 basis points from the corresponding period. The company recorded net income of $9 million and earnings per share of $0.18, compared with a net loss of $6.2 million and a loss per share of $0.13 in quarter 2 of fiscal year 2025, while adjusted earnings before interest, taxes, depreciation, and amortization rose 78% to $27.3 million.
The analyst consensus is “Buy,” with an average price target of $54.4 and a range of $50 to $60; the average is above the 52-week range high of $49.98, while the range low was $25.36. This valuation reflects expectations of continued growth and improved profitability, but it also assumes the company will overcome pressure in minimally invasive ablation and competition in AtriClip and achieve clinical and regulatory progress in BoxX-NoAF and LeAAPS; the absence of an established price-to-earnings ratio also makes the target range more dependent on execution against forward guidance.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Revenue rose 12.8% to $153.6 million, with the United States leading growth through a 13.6% increase to $125.6 million. U.S. pain management grew 27.8% to $27.1 million, and U.S. appendage management grew 14.4% to $51.6 million. U.S. open ablation sales also rose 12.1% to $40.9 million, supported by EnCompass.
cryoSPHERE MAX accounted for approximately 75% of U.S. pain management revenue in quarter 2 of fiscal year 2026 and helped the category achieve 27% global growth. The company ended the quarter with more than 700 active pain management accounts, while thoracic surgeries were still less than 25% penetrated according to management. cryoXT, which is intended for amputation procedures, still made a small contribution, but management expected a larger contribution during the second half of fiscal year 2026 following the start of adoption among vascular surgeons.
Enrollment surpassed 500 patients out of a target of 960 patients by July 23, 2026, and the company expected to complete it by the end of fiscal year 2026. Management is targeting a data readout in the first half of 2027, with a primary endpoint measuring an absolute difference of 10% in postoperative atrial fibrillation. It explained that the product follows the PMA pathway and that approval could take approximately one year after submitting the application to the FDA.
Automated analysis for informational purposes only — not investment advice.
The company recorded net income of $9 million and earnings per share of $0.18, compared with a net loss of $6.2 million and a loss per share of $0.13 in quarter 2 of fiscal year 2025. Adjusted earnings before interest, taxes, depreciation, and amortization rose 78% to $27.3 million, and gross margin reached 77.2%. The company also generated approximately $22 million in cash during the quarter and ended it with $167.8 million in cash and investments.
Minimally invasive ablation faces pressure from the market's shift toward PFA catheters and contributed only approximately $6 million to quarter 2 fiscal year 2026 revenue. In Europe, the United Kingdom and Germany experienced weakness, with cryoSPHERE losing reimbursement in the British market. New competition has also emerged in appendage management, and the company expects trials of competitor products during the second half of fiscal year 2026.
The company expects revenue of $602–610 million, equivalent to growth of approximately 12.5%–14% from fiscal year 2025. It raised its adjusted earnings before interest, taxes, depreciation, and amortization outlook to $85–89 million, with a margin of approximately 14% at the midpoint. It expects full-year net income and GAAP earnings per share of $0.05–0.13, and adjusted earnings per share of $0.24–0.32.